JP2021522801A5 - - Google Patents
Info
- Publication number
- JP2021522801A5 JP2021522801A5 JP2020561908A JP2020561908A JP2021522801A5 JP 2021522801 A5 JP2021522801 A5 JP 2021522801A5 JP 2020561908 A JP2020561908 A JP 2020561908A JP 2020561908 A JP2020561908 A JP 2020561908A JP 2021522801 A5 JP2021522801 A5 JP 2021522801A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- fragment
- sequence
- cdrs
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024059296A JP2024088696A (ja) | 2018-05-09 | 2024-04-02 | ヒトネクチン４に特異的な抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862668824P | 2018-05-09 | 2018-05-09 | |
| US62/668,824 | 2018-05-09 | ||
| PCT/IL2019/050508 WO2019215728A1 (en) | 2018-05-09 | 2019-05-06 | Antibodies specific to human nectin4 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059296A Division JP2024088696A (ja) | 2018-05-09 | 2024-04-02 | ヒトネクチン４に特異的な抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522801A JP2021522801A (ja) | 2021-09-02 |
| JP2021522801A5 true JP2021522801A5 (https=) | 2022-05-13 |
| JPWO2019215728A5 JPWO2019215728A5 (https=) | 2022-05-13 |
Family
ID=66690730
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561908A Pending JP2021522801A (ja) | 2018-05-09 | 2019-05-06 | ヒトネクチン４に特異的な抗体 |
| JP2024059296A Pending JP2024088696A (ja) | 2018-05-09 | 2024-04-02 | ヒトネクチン４に特異的な抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059296A Pending JP2024088696A (ja) | 2018-05-09 | 2024-04-02 | ヒトネクチン４に特異的な抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12077583B2 (https=) |
| EP (1) | EP3790900A1 (https=) |
| JP (2) | JP2021522801A (https=) |
| KR (2) | KR102892725B1 (https=) |
| CN (2) | CN119823267A (https=) |
| AU (1) | AU2019264965B2 (https=) |
| CA (1) | CA3097679A1 (https=) |
| IL (1) | IL277858B1 (https=) |
| WO (1) | WO2019215728A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| CN113527486B (zh) * | 2020-04-21 | 2025-12-02 | 迈威(上海)生物科技股份有限公司 | 一种抗Nectin-4的抗体及其应用 |
| CA3176497A1 (en) | 2020-05-07 | 2021-11-11 | Fatima MECHTA-GRIGORIOU | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| CA3182395A1 (en) * | 2020-06-18 | 2021-12-23 | Jay M. Short | Conditionally active anti-nectin-4 antibodies |
| US20230331867A1 (en) | 2020-09-04 | 2023-10-19 | Novarock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
| MX2023002805A (es) * | 2020-09-16 | 2023-03-16 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos. |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| AU2022253351A1 (en) | 2021-04-09 | 2023-10-12 | Boehringer Ingelheim International Gmbh | New scaffold for bifunctional molecules with improved properties |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| US20240269307A1 (en) * | 2021-04-26 | 2024-08-15 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-nectin-4 antibody and anti-nectin-4 antibody-drug conjugate, and medicinal use thereof |
| CA3226059A1 (en) * | 2021-06-29 | 2023-01-05 | Elpis Biopharmaceuticals | Anti-nectin4 antibodies and multi-specific protein complexes comprising such |
| WO2023009759A2 (en) * | 2021-07-30 | 2023-02-02 | R.P. Scherer Technologies, Llc | Antibody-drug conjugates and methods of use thereof |
| AU2022335573B2 (en) * | 2021-08-27 | 2026-02-19 | CSPC Megalith Biopharmaceutical Co., Ltd. | Anti-nectin-4 antibody, drug conjugate, and preparation method therefor and use thereof |
| AU2023208041A1 (en) * | 2022-01-12 | 2024-07-18 | Navi Bio-Therapeutics, Inc. | Antibody specific to nectin cell adhesion molecule 4 and uses thereof |
| EP4496593A1 (en) | 2022-03-23 | 2025-01-29 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
| WO2023198007A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Anti-nectin-4 antibodies and bispecific antibodies |
| WO2023198011A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Single domain anti-nectin-4 antibodies |
| CN116063498A (zh) * | 2022-04-27 | 2023-05-05 | 博际生物医药科技(杭州)有限公司 | 单域抗Nectin-4抗体 |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| US20260091114A1 (en) * | 2022-09-14 | 2026-04-02 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding nectin-4 |
| JP2025533506A (ja) | 2022-09-20 | 2025-10-07 | ネクチン セラピューティクス リミテッド | ネクチン－４に対するヒト化抗体及びその薬物コンジュゲート |
| KR20250143301A (ko) * | 2022-11-10 | 2025-10-01 | 센츄리 쎄라퓨틱스 인코포레이티드 | 항-넥틴4 키메라 항원 수용체를 갖는 유전자 조작 세포 및 이의 용도 |
| EP4646267A1 (en) * | 2023-01-03 | 2025-11-12 | Harpoon Therapeutics, Inc. | Nectin4 targeting trispecific protein for treatment of cancer |
| CN116381251B (zh) * | 2023-03-13 | 2024-06-25 | 柏定生物工程(北京)有限公司 | 一种肿瘤标志物诊断试剂盒及其诊断方法 |
| AU2024254671A1 (en) | 2023-03-30 | 2025-10-02 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| CN121358499A (zh) | 2023-03-30 | 2026-01-16 | Ose免疫疗法 | 靶向活化的免疫细胞以表达免疫细胞增强分子的基于脂质的纳米粒及其用途 |
| CN119462929A (zh) * | 2023-05-24 | 2025-02-18 | 深圳市先康达生命科学有限公司 | 靶向人Nectin4蛋白的抗体或其片段和应用 |
| CN119101156A (zh) * | 2023-06-08 | 2024-12-10 | 江苏迈威康新药研发有限公司 | 结合Nectin-4的抗体及其用途 |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| WO2025240789A1 (en) * | 2024-05-16 | 2025-11-20 | The Regents Of The University Of California | Chimeric antigen receptor targeting nectin4 |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025262250A1 (en) | 2024-06-20 | 2025-12-26 | Negio Therapeutics | Guanfacine derivatives and their uses |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4198507A (en) | 1978-11-13 | 1980-04-15 | Hoffmann-La Roche Inc. | Theophylline magnesium salicylate |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| HU215180B (hu) | 1992-01-23 | 1998-10-28 | Merck Patent Gmbh. | Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására |
| JP3659261B2 (ja) | 1994-10-20 | 2005-06-15 | モルフォシス・アクチェンゲゼルシャフト | 組換体タンパク質の多機能性複合体への標的化ヘテロ結合 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2222055A1 (en) | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Multimeric proteins |
| US5719867A (en) | 1995-06-30 | 1998-02-17 | Scientific-Atlanta, Inc. | Plural telephony channel baseband signal demodulator for a broadband communications system |
| EP1103181A1 (de) | 1999-11-25 | 2001-05-30 | Novartis AG | Kombination der N-Phenyl-N'-Benzoyl Harnstoff Derivaten und Avermectin für Parasiten Kontrolle. |
| EP1481993A1 (en) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
| WO2006014999A2 (en) | 2004-07-27 | 2006-02-09 | Five Prime Therapeutics, Inc. | Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease |
| JP5632582B2 (ja) * | 2006-12-14 | 2014-11-26 | 中外製薬株式会社 | 抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断 |
| US9399062B2 (en) * | 2011-01-18 | 2016-07-26 | Christopher D. Richardson | PVRL4 (Nectin4) is a receptor for measles virus |
| HK1210964A1 (en) | 2012-12-04 | 2016-05-13 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| AU2015305754B2 (en) | 2014-08-19 | 2018-10-25 | Merck Sharp & Dohme Llc | Anti-tigit antibodies |
| US10227408B2 (en) | 2015-02-19 | 2019-03-12 | Compugen Ltd. | Anti-PVRIG antibodies and methods of use |
| CN108137691B (zh) | 2015-09-02 | 2021-10-19 | 耶路撒冷希伯来大学伊萨姆研究发展有限公司 | 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体 |
| US10675357B2 (en) * | 2015-09-09 | 2020-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to nectin-4 and uses thereof |
| MX2018010445A (es) | 2016-03-01 | 2019-10-17 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Anticuerpos especificos del receptor de poliovirus humano (rvp). |
| US11274160B2 (en) | 2017-03-02 | 2022-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to Nectin-4 and uses thereof |
| WO2022056304A1 (en) | 2020-09-10 | 2022-03-17 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using nectin-4 specific fusion proteins |
-
2019
- 2019-05-06 KR KR1020207031656A patent/KR102892725B1/ko active Active
- 2019-05-06 CA CA3097679A patent/CA3097679A1/en active Pending
- 2019-05-06 KR KR1020257039502A patent/KR20250173584A/ko active Pending
- 2019-05-06 JP JP2020561908A patent/JP2021522801A/ja active Pending
- 2019-05-06 WO PCT/IL2019/050508 patent/WO2019215728A1/en not_active Ceased
- 2019-05-06 CN CN202411898788.2A patent/CN119823267A/zh active Pending
- 2019-05-06 EP EP19728137.1A patent/EP3790900A1/en active Pending
- 2019-05-06 IL IL277858A patent/IL277858B1/en unknown
- 2019-05-06 AU AU2019264965A patent/AU2019264965B2/en active Active
- 2019-05-06 US US17/052,960 patent/US12077583B2/en active Active
- 2019-05-06 CN CN201980029788.XA patent/CN112088167B/zh active Active
-
2024
- 2024-04-02 JP JP2024059296A patent/JP2024088696A/ja active Pending
- 2024-07-23 US US18/780,731 patent/US20240376202A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522801A5 (https=) | ||
| JPWO2019215728A5 (https=) | ||
| AU2016281641B2 (en) | Novel PD-1 immune modulating agents | |
| JP2019511212A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| JP2021531764A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2018532383A5 (https=) | ||
| RU2018134065A (ru) | Антитела, специфические к рецептору полиовируса (pvr) человека | |
| JP2020527332A5 (https=) | ||
| JP2019533719A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| JP2018508483A5 (https=) | ||
| CN108348521A (zh) | 用于治疗癌症的5-溴-2,6-二-(1h-吡唑-1-基)嘧啶-4-胺 | |
| FI3941946T3 (fi) | Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja | |
| JP2013519367A5 (https=) | ||
| JP2021512107A5 (https=) | ||
| JP2021520201A5 (https=) | ||
| JP2015509960A5 (https=) | ||
| JP2021533796A5 (https=) | ||
| JP2025148452A5 (https=) | ||
| JPWO2020144697A5 (https=) | ||
| KR20240038769A (ko) | 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법 | |
| IL277899B2 (en) | Methods and preparations for treating yellow fever |